Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 215,621 | 228,586 | 230,042 | 221,349 | 237,113 |
| Receivables | N/A | N/A | 18,000 | N/A | 100 |
| TOTAL | $222,357 | $231,220 | $251,440 | $226,074 | $241,417 |
| Non-Current Assets | |||||
| PPE Net | 1,652 | 1,456 | 1,335 | 1,295 | 1,253 |
| Other Non-Current Assets | 2,652 | 2,466 | 2,476 | 2,593 | 791 |
| TOTAL | $4,304 | $3,922 | $3,811 | $3,888 | $2,044 |
| Total Assets | $226,661 | $235,142 | $255,251 | $229,962 | $243,461 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 7,660 | 3,064 | 3,645 | 2,811 | 1,372 |
| Accrued Expenses | 7,123 | 7,700 | 7,339 | 7,361 | 5,710 |
| TOTAL | $15,453 | $11,648 | $11,846 | $11,015 | $7,531 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 231 | 469 | 274 |
| TOTAL | $N/A | $N/A | $231 | $469 | $274 |
| Total Liabilities | $15,453 | $11,648 | $12,077 | $11,484 | $7,805 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 25,757 | 24,035 | 24,000 | 23,399 | 23,338 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -175,207 | -147,941 | -123,755 | -116,815 | -96,518 |
| TOTAL | $211,208 | $223,494 | $243,174 | $218,478 | $235,656 |
| Total Liabilities And Equity | $226,661 | $235,142 | $255,251 | $229,962 | $243,461 |